3 active not recruiting, 2 recruiting, 1 not yet recruiting. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Active not recruiting 3, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Prostate Carcinoma: new trials by email Literature Review of Prostate Carcinoma trials Research Report on Prostate Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer ultiparametric Magnetic Resonance Imaging, Perflutren lipid microsphere, Transrectal Ultrasound - Prostate Carcinoma | Phase 3 | Not yet recruiting | Thomas Jefferson University | 300 | 2026-10-01 | 2026-08-25 |
| Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer Biospecimen Collection, Magnetic Resonance Imaging, Photon Beam Radiation Therapy - Prostate Carcinoma | Phase 3 | Recruiting | Mayo Clinic | 108 | 2025-02-02 | 2026-10-02 |
| Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers Low-intensity Extracorporeal Shock Wave Therapy (LiESWT), PDE5 inhibitor (tadalafil) - Prostate Carcinoma, Erectile Function | Phase 3 | Recruiting | Regina Elena Cancer Institute | 158 | 2023-09-15 | 2026-08-14 |
| Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount) Perflutren Lipid Microspheres, Ultrasound - Prostate Carcinoma | Phase 3 | Active not recruiting | Thomas Jefferson University | 70 | 2022-06-15 | 2025-09-04 |
| Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study Darolutamide, Goserelin Acetate, Leuprolide Acetate - Prostate Carcinoma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 27 | 2021-03-01 | 2026-07-28 |
| Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer Exercise Intervention, Methylphenidate, Placebo - Prostate Carcinoma | Phase 2 / Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 200 | 2019-03-25 | 2026-11-04 |
Prostatic Neoplasms (6) · Urogenital Neoplasms (1)
Genital Diseases (6) · Genital Diseases, Male (6) · Genital Neoplasms, Male (6) · Male Urogenital Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Prostatic Diseases (6) · Urogenital Diseases (6) · Urogenital Neoplasms (5) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
perflutren (2) · Goserelin (1) · High-Energy Shock Waves (1) · Leuprolide (1) · Magnetic Resonance Spectroscopy (1) · Methylphenidate (1) · Phosphodiesterase 5 Inhibitors (1) · Photons (1) · Radiation (1) · Specimen Handling (1) · Tadalafil (1) · Triptorelin Pamoate (1) · Ultrasound, High-Intensity Focused, Transrectal (1) · darolutamide (1) · luprolide acetate gel depot (1)
Thomas Jefferson University (2) · ECOG-ACRIN Cancer Research Group (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Regina Elena Cancer Institute (1)
United States (5) · Netherlands (2) · Italy (1)
Alicia K Morgans (1) · Nathan Y. Yu, MD (1) · Sriram Yennu, MD (1)
R01CA252311 (1), U10CA180820 (1)